Leerink Partnrs Forecasts Weaker Earnings for Tourmaline Bio

Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Equities researchers at Leerink Partnrs dropped their FY2026 EPS estimates for shares of Tourmaline Bio in a note issued to investors on Wednesday, May 21st. Leerink Partnrs analyst T. Smith now expects that the company will post earnings of ($4.45) per share for the year, down from their previous forecast of ($4.28). The consensus estimate for Tourmaline Bio's current full-year earnings is ($3.02) per share. Leerink Partnrs also issued estimates for Tourmaline Bio's FY2027 earnings at ($5.65) EPS, FY2028 earnings at ($7.45) EPS and FY2029 earnings at ($4.61) EPS.

TRML has been the subject of several other reports. Wedbush raised their price objective on shares of Tourmaline Bio from $42.00 to $43.00 and gave the stock an "outperform" rating in a report on Friday, March 14th. Chardan Capital reissued a "buy" rating and set a $70.00 price objective on shares of Tourmaline Bio in a report on Monday, May 5th. HC Wainwright reissued a "buy" rating and set a $50.00 price objective on shares of Tourmaline Bio in a report on Monday, May 5th. Finally, Lifesci Capital assumed coverage on shares of Tourmaline Bio in a report on Monday, February 24th. They set an "outperform" rating and a $58.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tourmaline Bio presently has a consensus rating of "Buy" and a consensus price target of $49.33.

Tourmaline Bio Trading Up 1.0%

TRML stock traded up $0.15 during mid-day trading on Monday, hitting $15.64. 191,769 shares of the company were exchanged, compared to its average volume of 275,308. The company has a market capitalization of $401.71 million, a PE ratio of -5.55 and a beta of 2.11. Tourmaline Bio has a twelve month low of $11.56 and a twelve month high of $29.79. The firm has a fifty day simple moving average of $15.38 and a 200 day simple moving average of $17.76.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) last released its quarterly earnings results on Friday, May 2nd. The company reported ($0.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.91) by $0.02.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of TRML. Tower Research Capital LLC TRC boosted its holdings in shares of Tourmaline Bio by 297.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,646 shares of the company's stock valued at $33,000 after buying an additional 1,232 shares during the period. KLP Kapitalforvaltning AS acquired a new position in Tourmaline Bio during the 4th quarter valued at about $47,000. Brooklyn Investment Group boosted its stake in Tourmaline Bio by 148.9% during the 1st quarter. Brooklyn Investment Group now owns 3,923 shares of the company's stock valued at $60,000 after purchasing an additional 2,347 shares during the period. Virtus ETF Advisers LLC acquired a new position in Tourmaline Bio during the 4th quarter valued at about $64,000. Finally, GAMMA Investing LLC boosted its stake in Tourmaline Bio by 4,481.7% during the 1st quarter. GAMMA Investing LLC now owns 7,514 shares of the company's stock valued at $114,000 after purchasing an additional 7,350 shares during the period. 91.89% of the stock is owned by institutional investors and hedge funds.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.